Cue Biopharma earnings missed by $3.39, revenue fell short of estimates
Cue Biopharma (CUE) reported Q3 EPS of -$4.74, missing estimates by $3.39, with revenue of $10K, below the $1.55M consensus. The stock is down 42.71% over 3 months and 18.12% over 12 months. InvestingPro rates its financial health as weak.
How this was made
The 30-second read
Why it matters
The magnitude of the EPS miss and the reported revenue shortfall are likely to dominate trader focus on solvency risk and the credibility of the path to meaningful revenue.
Market read
Traders can reassess valuation and near-term risk after the company’s quarterly print missed both EPS and revenue expectations.
What to watch
The article does not include guidance, cash balance, burn rate, or management commentary, which are often decisive for biotech post-earnings direction.
Background
The piece summarizes Cue Biopharma’s Q3 results versus analyst consensus and notes weak financial health.
Ticker impact
Cue Biopharma reported Q3 EPS of -4.740, missing the -1.350 estimate, and revenue of $10K versus $1.55M consensus.
Likely downward pressure as the market reprices the company’s revenue trajectory and cash-burn expectations after the miss.
The article provides the company’s own quarterly EPS and revenue figures versus consensus, which are direct drivers of post-earnings sentiment and valuation for a micro/small-cap biotech.
Market effects
Reinforces risk-off sentiment toward pre-commercial or revenue-light biotech names when quarterly revenue prints miss sharply.
Limited spillover expected beyond US small-cap biotech sentiment.
Low, company-specific earnings miss with no cross-market catalyst described.
Counterpoint
If the revenue shortfall reflects timing (e.g., delayed recognition) rather than demand collapse, the stock could stabilize on any qualitative commentary not captured here.
Key entities
- companyCue Biopharma
NASDAQ-listed biotech reporting Q3 EPS and revenue versus consensus.


